SPDR S&P Biotech ETF
642 hedge funds and large institutions have $11.4B invested in SPDR S&P Biotech ETF in 2021 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 254 increasing their positions, 170 reducing their positions, and 77 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
6% less capital invested
Capital invested by funds: $12.1B → $11.4B (-$691M)
19.76% less ownership
Funds ownership: 176.26% → 156.5% (-20%)
54% less call options, than puts
Call options by funds: $1.35B | Put options by funds: $2.93B
Holders
642
Holding in Top 10
20
Calls
$1.35B
Puts
$2.93B
Top Buyers
| 1 | +$873M | |
| 2 | +$790M | |
| 3 | +$218M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$126M |
| 5 |
SG Americas Securities
New York
|
+$68.7M |
Top Sellers
| 1 | -$697M | |
| 2 | -$642M | |
| 3 | -$281M | |
| 4 |
Wells Fargo
San Francisco,
California
|
-$271M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$241M |